University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Matthew R. Cooperberg, MD, MPH

Matthew R. Cooperberg, MD, MPH

Associate Professor, Department of Urology, UCSF
Helen Diller Family Chair in Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

Health Services

Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.

Prostate Cancer Risk Assessment and Comparative Effectiveness Research

Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.

Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.

Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.

Survivorship

Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.

Small Renal Masses

In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.

Education

Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy


Professional Experience

  • 2000-01
    Internship in General Surgery (preliminary to Urology), Yale University, New Haven, CT
  • 2001-03
    Research Fellowship in Genitourinary Oncology, University of California, San Francisco, CA
  • 2004-08
    Residency in Urology, University of California, San Francisco, CA
  • 2008-09
    Clinical Fellow, Genitourinary Oncology, University of California, San Francisco, CA
  • 2009-2013
    Assistant Professor, Department of Urology, University of California, San Francisco, CA
  • 2013-present
    Associate Professor, Department of Urology, University of California, San Francisco, CA

Honors & Awards

  • 1995
    College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
  • 1996
    American Cancer Society Research Fellowship
  • 1999
    AMA John Conley Ethics Essay Contest, honorable mention
  • 2003
    UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
  • 2004
    UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
  • 2005
    Northern California Urology Resident Research Symposium, 1st place, Clinical Research
  • 2006
    Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
  • 2007
    AUA Gerald P. Murphy Prostate Scholar
  • 2007
    Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
  • 2007
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Society of Urologic Oncology Poster Session, 3rd place overall
  • 2008
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Western Section AUA Poster Session I, 1st place
  • 2017
    2016 physician award, Marin Prostate Cancer Information and Support Group

Selected Publications

  1. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Mar 09.
    View on PubMed
  2. Tyson MD, Koyama T, Lee D, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen V, Conwill R, McCollum D, Penson DF, Barocas DA. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol. 2018 Feb 28.
    View on PubMed
  3. Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Feb 23.
    View on PubMed
  4. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018 Feb 09.
    View on PubMed
  5. McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 Feb 08.
    View on PubMed
  6. Cooperberg MR. How Should a Man with Prostate Cancer Choose his Surgeon? Eur Urol. 2018 Feb 03.
    View on PubMed
  7. Avulova S, Zhao Z, Lee D, Huang LC, Koyama T, Hoffman KE, Conwill RM, Wu XC, Chen V, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Resnick MJ, Penson DF, Barocas DA. The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. J Urol. 2017 Dec 16.
    View on PubMed
  8. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424.
    View on PubMed
  9. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 Apr; 21(1):4-21.
    View on PubMed
  10. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672.
    View on PubMed
  11. Downer MK, Stampfer MJ, Cooperberg MR. Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not? JAMA Oncol. 2017 12 01; 3(12):1623-1624.
    View on PubMed
  12. Cooperberg MR. Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. Eur Urol. 2017 Nov 28.
    View on PubMed
  13. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 Jan 02; 168(1):1-9.
    View on PubMed
  14. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 Apr; 73(4):572-582.
    View on PubMed
  15. Herlemann A, Washington SL, Eapen RS, Cooperberg MR. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier. Urol Clin North Am. 2017 Nov; 44(4):547-555.
    View on PubMed
  16. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate. 2017 Dec; 77(16):1592-1600.
    View on PubMed
  17. Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One. 2017; 12(10):e0185535.
    View on PubMed
  18. Cooperberg MR. Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care. JAMA Oncol. 2017 Oct 01; 3(10):1398-1399.
    View on PubMed
  19. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582.
    View on PubMed
  20. Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll PR, Breyer BN. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urol Oncol. 2017 Nov; 35(11):663.e9-663.e14.
    View on PubMed

Go to UCSF Profiles, powered by CTSI